Read here for two sustainable 8-9% yield stocks with recent dips. Learn why they offer high return potential with low risk.

Stocks may appear overvalued at face value, but strong long-term earnings growth potential could justify current prices. Read ...

U.S. stocks end the week on a high, as S&P 500 reclaims the 6,000-point mark for the first time since February. Read more ...

Fresenius offers international diversification, stable healthcare exposure, and upside from a strategic pivot. Find out why ...

USCL ETF has climate-conscious exposure to top companies like Nvidia and Microsoft with a low expense ratio. Read an in-depth ...

TFI International remains a strong buy with solid cash flow, strategic growth, and new buying opportunities amid a recovering ...

CAVA's expansion boosts revenue, but slowing sales and high valuation raise concerns. Read here for an analysis of CAVA stock ...

Northwest Pipe's growth is set to surge in FY25, with improving margins, strong order momentum, and favorable stock valuation ...

Omada Health shows strong growth and innovation in chronic care but remains unprofitable with valuation, churn. See why OMDA ...

AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.

Aker ASA remains discounted to NAV, with steps like the Solstad IPO and Cognite's U.S. shift supporting value. See why AKAAF ...

The median risk of default for publicly traded US companies rose across most sectors from the end of March through the end of ...